Cartesian Therapeutics, Inc. (RNAC): R&D Expense
$58.03M
Year ended 2025-12-31
$68.39M
Trailing 12 months to 2026-06-30
-7.1%
3-year compound annual growth
+1.3%
5-year compound annual growth
+9.7%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $58.03M | +28.7% | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $45.10M | -36.7% | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $71.26M | -1.5% | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | $72.38M | +5.3% | 2024-03-07, From 2022-01-01 |
| 2021-12-31 | $68.74M | +26.1% | 2024-03-07, From 2021-01-01 |
| 2020-12-31 | $54.51M | +27.5% | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | $42.74M | -10.4% | 2022-03-10, From 2019-01-01 |
| 2018-12-31 | $47.69M | +5.6% | 2021-03-12, From 2018-01-01 |
| 2017-12-31 | $45.16M | +52.1% | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | $29.70M | +29.3% | 2019-03-15, From 2016-01-01 |
| 2015-12-31 | $22.98M | +119.1% | 2018-03-15, From 2015-01-01 |
| 2014-12-31 | $10.49M | n/a | 2017-03-28, From 2014-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | $58.03M | +28.7% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $136.81M | +117.3% |
| Xenetic Biosciences, Inc. (XBIO) | 2025-12-31 | $3.07M | -6.8% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $18.12M | -23.6% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $38.20M | -1.6% |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $11.80M | -12.4% |
| Korsana Biosciences, Inc. (KRSA) | 2025-12-31 | $959.0K | +235.3% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $145.64M | +75.2% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $8.58M | +16.8% |
Compare RNAC, UPB, XBIO, GOVX side by side · Screen every company in Pharmaceutical Preparations ↗